These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 29057508

  • 1. Impact of antiviral prophylaxis in adults Epstein-Barr Virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: a retrospective cohort study.
    Ville S, Imbert-Marcille BM, Coste-Burel M, Garandeau C, Meurette A, Cantarovitch D, Giral M, Hourmant M, Blancho G, Dantal J.
    Transpl Int; 2018 May; 31(5):484-494. PubMed ID: 29057508
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
    Humar A, Hébert D, Davies HD, Humar A, Stephens D, O'Doherty B, Allen U.
    Transplantation; 2006 Mar 27; 81(6):856-61. PubMed ID: 16570008
    [Abstract] [Full Text] [Related]

  • 6. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S, Zafar MN, Best J, Reddy HK.
    J Cardiovasc Pharmacol Ther; 2006 Mar 27; 11(1):77-83. PubMed ID: 16703222
    [Abstract] [Full Text] [Related]

  • 7. (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation.
    Höcker B, Böhm S, Fickenscher H, Küsters U, Schnitzler P, Pohl M, John U, Kemper MJ, Fehrenbach H, Wigger M, Holder M, Schröder M, Feneberg R, Köpf-Shakib S, Tönshoff B.
    Transpl Int; 2012 Jul 27; 25(7):723-31. PubMed ID: 22533698
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study.
    Schachtner T, Reinke P.
    Transpl Infect Dis; 2016 Dec 27; 18(6):881-888. PubMed ID: 27632022
    [Abstract] [Full Text] [Related]

  • 11. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
    Babel N, Gabdrakhmanova L, Hammer M, Rosenberger C, Oppert M, Volk HD, Reinke P.
    Transpl Infect Dis; 2005 Dec 27; 7(3-4):133-6. PubMed ID: 16390402
    [Abstract] [Full Text] [Related]

  • 12. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T, Zwick DL, Rothberg PG, Warady BA.
    Pediatr Nephrol; 1999 Nov 27; 13(9):748-54. PubMed ID: 10603113
    [Abstract] [Full Text] [Related]

  • 13. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
    Peters AC, Akinwumi MS, Cervera C, Mabilangan C, Ghosh S, Lai R, Iafolla M, Doucette K, Preiksaitis JK.
    Transplantation; 2018 Sep 27; 102(9):1553-1562. PubMed ID: 29485513
    [Abstract] [Full Text] [Related]

  • 14. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
    Smith JM, Corey L, Healey PJ, Davis CL, McDonald RA.
    Transplantation; 2007 Jun 15; 83(11):1423-8. PubMed ID: 17565314
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients.
    Morton M, Coupes B, Roberts SA, Klapper PE, Byers RJ, Vallely PJ, Ryan K, Picton ML.
    Transplantation; 2013 Feb 15; 95(3):470-8. PubMed ID: 23222821
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
    Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, Crouch J, Bia MJ, Kliger AS, Lorber MI.
    Transplantation; 1997 Sep 27; 64(6):848-52. PubMed ID: 9326409
    [Abstract] [Full Text] [Related]

  • 20. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol.
    Birkeland SA, Andersen HK, Hamilton-Dutoit SJ.
    Transplantation; 1999 May 15; 67(9):1209-14. PubMed ID: 10342310
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.